SYSTM Wealth Solutions LLC Grows Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

SYSTM Wealth Solutions LLC increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 4.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,771 shares of the medical instruments supplier’s stock after purchasing an additional 72 shares during the period. SYSTM Wealth Solutions LLC’s holdings in Becton, Dickinson and Company were worth $414,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in BDX. Nordea Investment Management AB increased its holdings in shares of Becton, Dickinson and Company by 277.3% during the 1st quarter. Nordea Investment Management AB now owns 1,936,654 shares of the medical instruments supplier’s stock valued at $478,295,000 after purchasing an additional 1,423,353 shares in the last quarter. PineStone Asset Management Inc. increased its holdings in Becton, Dickinson and Company by 141.6% in the second quarter. PineStone Asset Management Inc. now owns 1,345,873 shares of the medical instruments supplier’s stock valued at $314,544,000 after buying an additional 788,735 shares in the last quarter. M&G Plc purchased a new stake in shares of Becton, Dickinson and Company during the 1st quarter worth about $173,692,000. Bank of New York Mellon Corp grew its position in shares of Becton, Dickinson and Company by 8.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock valued at $1,031,167,000 after acquiring an additional 346,720 shares during the period. Finally, Magnetar Financial LLC purchased a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at about $75,493,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $231.58 on Thursday. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. The stock has a market cap of $66.93 billion, a P/E ratio of 51.01, a PEG ratio of 1.91 and a beta of 0.42. The company has a 50-day moving average price of $235.23 and a 200 day moving average price of $235.54. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $269.52.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 EPS for the quarter, beating the consensus estimate of $3.31 by $0.19. The firm had revenue of $4.99 billion for the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.96 EPS. Sell-side analysts anticipate that Becton, Dickinson and Company will post 13.1 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be issued a $0.95 dividend. The ex-dividend date is Monday, September 9th. This represents a $3.80 annualized dividend and a yield of 1.64%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 83.70%.

Wall Street Analyst Weigh In

BDX has been the subject of several recent analyst reports. Evercore ISI cut their price target on shares of Becton, Dickinson and Company from $290.00 to $285.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Raymond James decreased their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Stifel Nicolaus lifted their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Finally, The Goldman Sachs Group began coverage on shares of Becton, Dickinson and Company in a research report on Thursday, May 30th. They issued a “buy” rating and a $274.00 target price for the company. One analyst has rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $279.50.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.